SynthesisFrontiers in behavioral neuroscience2026
Biomarkers of post-stroke cognitive impairment-a systematic literature review.
Synthesis in Frontiers in behavioral neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-stroke cognitive impairment (PSCI) severely affects quality of life and prognosis in stroke survivors, yet reliable predictive, diagnostic and prognostic tools remain limited. Recent advances suggest that molecular, genetic, and imaging-based biomarkers may improve prediction and management of PSCI. The purpose of this systematic review was to provide a synthesis of the current evidence on biomarkers related to PSCI, aiming to highlight knowledge gaps and future research directions. Methods: We conducted a systematic review of observational cohort, cross-sectional, case-control and interventional studies investigating biomarkers associated with PSCI and post-stroke dementia. Eligible studies enrolled patients with acute ischemic or hemorrhagic stroke and reported cognitive outcomes with biomarker assessments in blood, or other body fluids, or neuroimaging. Screening followed PRISMA guidelines. Data extraction included study design, population characteristics, biomarkers, and cognitive outcomes. Biomarkers were clustered by type for evidence synthesis. Results: Of 834 screened studies, 154 were included (99 cohorts, 19 case-control, 35 cross-sectional, 1 interventional; Conclusion: Several body-fluid-based, genetic, and imaging biomarkers demonstrate potential for the prediction of PSCI. However, clinical utility remains constrained by study heterogeneity, lack of standardization and residual confounding. Standardized protocols for cognitive assessments and biomarker timing, as well as multi-center longitudinal studies, are essential to validate and translate these biomarkers into routine clinical care. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025642710, identifier CRD42025642710.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.